Research programme: immunological disorder therapeutics - Synnovation Therapeutics
Latest Information Update: 24 Oct 2025
At a glance
- Originator Synnovation Therapeutics
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Immunological disorders
Most Recent Events
- 07 Oct 2025 Early research in Immunological disorders in USA (unspecified route)